Augustine Therapeutics is proud to sponsor the 2023 Global CMT Research Convention, organized by the US CMT Research Foundation, to be held on September 22nd & 23rd at the Royal Sonesta Boston, Cambridge, MA.
The event is gathering researchers, biotech and pharma companies, investors and patients to discuss widely the latest research and development towards finding a cure for Charcot-Marie-Tooth patients. This yearly convention enhances the scope and possibilities of research discoveries as a step forward for the people who are living with CMT!
Our CEO, Dr. Sylvain Celanire, will participate as a panel speaker during both Scientific and Patient Community Days:
- Pushing boundaries in CMT research of early biotech companies – Friday, Sept 22nd afternoon.
- Patient-Powered Perspectives: Biotech Insights on CMT and Collaborating with Patients – Saturday, Sept 23rd afternoon.
We feel extremely thankful to CMT Research Foundation for providing such a global platform. This boosts awareness amongst every individual going through CMT and helps us work with that objective.
Augustine Therapeutic is currently advancing AGT100216 clinical candidate towards First-in-man clinical trial. AGT100216 is a highly selective, orally bioavailable, and safe HDAC6 inhibitor belonging to a unique and unprecedented chemical class. We have recently communicated at the 2023 PNS conference held in Copenhagen the outstanding preclinical efficacy of AGT100216 , not only halting CMT1A disease progression but also significantly reversing disease phenotype and rescuing axonal integrity in a dose-dependent manner after only 4 weeks of low oral daily treatment.
Find out details of the event and agenda here: Global CMT Research Convention
